Web3 AGO Study Group and West London Gynecological Cancer Centre; Imperial College Healthcare NHS Trust, London, UK. 4 AGO Study Group and Department of Gynecologic Oncology, Charite Comprehensive Cancer Center Berlin, Berlin, Germany. 5 MANGO and Department of Gynecology, Istituto Europeo di Oncologia, Milano, Italy. WebJun 7, 2024 · As such, investigators launched the AGO-OVAR 17 trial in order to further examine if prolonging treatment with bevacizumab for up to 30 months would improve …
Publizierte Studien AGO Research GmbH
WebDec 3, 2024 · DESKTOP III was the first prospectively randomized trial showing an overall survival (OS) benefit of debulking surgery in recurrent ovarian cancer. 1 Cytoreductive surgery for patients with a platinum-free interval of >6 months and selected by the AGO score significantly prolonged both OS and progression-free survival. WebFeb 2, 2024 · For the latter, the largest percentage (28.9%) was attributed to SLC4A11, with GBP5 and KRT4 exhibiting a high ... Vienna, Austria) under the R Studio desktop application (version 1.4.1717, RStudio, Boston, MA, USA). 4.2. ... A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int. J. … foreign related literature
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone …
WebThe primary endpoint was investigator-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumors version 1.1. Efficacy data were analysed in … WebJun 8, 2024 · Patients and methods. Data from AURELIA (n = 326), a randomized trial of chemotherapy with or without bevacizumab, were used to identify baseline QoL domains [EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 and OV28] that were significantly associated with overall survival in multivariable Cox … WebMethods: AGO-OVAR 28/ ENGOT-ov57 (NCT05009082; EudraCT Number: 2024-001271-16) is an Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group led, international, multicenter, randomized, prospective phase III trial within the ENGOT trial network. The trial population is composed of adult pts with newly diagnosed, advanced … did the signs change